Intervention

nivolumab

ClinicalTrials.gov intervention label

Clinical trials30
Recruiting1
Common conditions25
Lead sponsors shown15

Clinical trials

30 shown
Patient Preference for Subcutaneous vs. Intravenous Immune TherapyNCT07223424 · 2025-11-04
RECRUITING
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and CanadaNCT07718139 · 2026-02-28
ACTIVE_NOT_RECRUITING
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.NCT05834348 · 2023-06-23
COMPLETED
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyNCT04151563 · 2021-04-15
WITHDRAWN
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid TumorsNCT04349267 · 2020-07-14
COMPLETED
A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor TypesNCT04311710 · 2020-06-25
TERMINATED
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant MesotheliomaNCT04300244 · 2020-05-04
ACTIVE_NOT_RECRUITING
Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung CancerNCT04271384 · 2020-02-12
COMPLETED
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast CancerNCT04109066 · 2019-11-18
COMPLETED
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid TumorsNCT04336241 · 2019-10-17
ACTIVE_NOT_RECRUITING
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLCNCT04069936 · 2019-10-15
TERMINATED
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by SurgeryNCT04026412 · 2019-10-08
COMPLETED
A Study of a Personalized Cancer Vaccine Targeting Shared NeoantigensNCT03953235 · 2019-07-18
COMPLETED
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid TumorsNCT03970382 · 2019-07-03
SUSPENDED
A Study of a Personalized Neoantigen Cancer VaccineNCT03639714 · 2019-02-13
COMPLETED
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid TumorsNCT03565445 · 2018-07-02
COMPLETED
Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer PatientsNCT03509584 · 2018-06-07
TERMINATED
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor MalignanciesNCT03435640 · 2018-03-15
TERMINATED
A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC PatientsNCT03486119 · 2018-02-05
COMPLETED
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsNCT03169738 · 2018-02-01
WITHDRAWN
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate CancerNCT03338790 · 2017-12-19
COMPLETED
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)NCT03767348 · 2017-09-20
ACTIVE_NOT_RECRUITING
Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal MelanomaNCT02831933 · 2017-02-15
TERMINATED
Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)NCT02944396 · 2016-12-23
COMPLETED
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced MalignanciesNCT02712905 · 2016-05-05
TERMINATED
A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLCNCT02852083 · 2016-01-01
UNKNOWN
Nivolumab in Patients With Recurrent Malignant MesotheliomaNCT02497508 · 2015-07-01
COMPLETED
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)NCT02423954 · 2015-04-01
TERMINATED
Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCsNCT02350764 · 2015-01-20
COMPLETED
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsNCT02009449 · 2013-11-15
COMPLETED

Common conditions

Non-small Cell Lung Cancer8Non Small Cell Lung Cancer4Colorectal Cancer3Melanoma3Renal Cell Carcinoma3Breast Cancer2Cancer2Colorectal Carcinoma2Non-Small Cell Lung Cancer (NSCLC)2Pancreatic Cancer2Prostate Cancer2Solid Tumor2Advanced Cancer1Advanced Solid Tumor1Advanced Solid Tumors1Advanced Stage Non-small Cell Lung Cancer1Cancer of Lung1Cancer, Lung1Carcinoma, Non-small Cell Lung Cancer1Cervical Cancer1Colo-rectal Cancer (dMMR/MSI-H CRC)1Cutaneous Melanoma1Endometrial1Esophageal Adenocarcinoma1Esophageal Cancer1

Trial status mix

COMPLETED14
TERMINATED7
ACTIVE_NOT_RECRUITING4
WITHDRAWN2
RECRUITING1
SUSPENDED1
UNKNOWN1

Phase mix

PHASE218
PHASE115
PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.